VIRO-immunological outcomes after 13-valent pneumococcal vaccination in HIV-1-infected individuals on stable virological suppression

Raffaele Dell'Acqua, Laura Galli, Andrea Poli, Andrea Mastrangelo, Monica Guffanti, Patrizia Tadini, Daniela Zandona, Anna Danise, Nicola Gianotti, Adriano Lazzarin, Antonella Castagna, Silvia Nozza

Research output: Contribution to journalArticlepeer-review


Background:Very limited data are available on the immunovirological outcomes after 13-valent pneumococcal conjugate vaccine (PCV13) in antiretroviral therapy (ART)-treated patients. The aim of this study was to assess the immune-virological outcomes in HIV-1-infected ART-treated patients on stable virological suppression who underwent pneumococcal conjugate vaccination.Methods:Retrospective, cohort study on ART-treated HIV-1-infected individuals, age at least 18 years, with three consecutive determinations of HIV-RNA less than 50 copies/ml before the administration of PCV13 (baseline) at San Raffaele Hospital and with at least two HIV-RNA values after vaccination.Results:Overall 1197 patients underwent PCV13 vaccination. During 6-month of follow-up (594 person-years of follow-up, PYFU), 12 confirmed virological failure and 35 viral blips were observed; the overall incidence rate of confirmed virological failure was 2.02 (95% confidence interval: 0.88-3.16) per 100-PYFU and the incidence rate of viral blips was 5.89 (95% confidence interval: 3.94-7.84) per 100-PYFU. Median CD4+ cell count change from baseline at 6 months was +10 cells/μl (interquartile range -67, +111; P = 0.0002). Median change in CD4+/CD8+ ratio was +0.02 (interquartile range -0.06, +0.11; P < 0.001).Conclusion:Viral blips and confirmed virological failures were rarely observed in patients on stable virological suppression in the first 6 months following vaccination with PCV13. In addition, no decrease of CD4+ cell count and CD4+/CD8+ ratio was recorded.

Original languageEnglish
Pages (from-to)1987-1994
Number of pages8
Issue number13
Publication statusPublished - Nov 1 2019


  • 13-valent pneumococcal conjugate vaccine
  • confirmed virological failure
  • HIV infection
  • vaccine
  • viral blip
  • virological suppression

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases


Dive into the research topics of 'VIRO-immunological outcomes after 13-valent pneumococcal vaccination in HIV-1-infected individuals on stable virological suppression'. Together they form a unique fingerprint.

Cite this